Company Overview
About Altay Therapeutics
Altay Therapeutics is a Cambridge, Massachusetts-based biotechnology company — backed by Y Combinator (W20) with $6.71 million raised including a $3 million seed round — developing first-in-class small molecule therapeutics that target transcription factors, historically considered "undruggable" proteins due to their lack of conventional binding sites, for rare genetic diseases and oncology indications. Founded in 2019, Altay's lead programs focus on facioscapulohumeral muscular dystrophy (FSHD) — a rare, progressive muscle disease affecting 1 in 8,500 people with no approved treatments — and cancer targets where transcription factor dysregulation drives tumor growth.
Business Model & Competitive Advantage
Altay's transcription factor inhibition platform addresses one of the fundamental challenges in drug discovery: transcription factors are proteins that regulate gene expression and are frequently mutated or overactivated in disease, but their flat, featureless binding surfaces have resisted conventional small molecule drug design for decades. Altay's approach uses proprietary computational modeling and medicinal chemistry to identify cryptic binding sites and design small molecules that disrupt protein-protein interactions or DNA binding of disease-relevant transcription factors. For FSHD specifically, the disease is driven by toxic expression of the DUX4 transcription factor — inhibiting DUX4 expression or activity represents the mechanistic target that Altay's lead compounds address.
Competitive Landscape 2025–2026
In 2025, Altay Therapeutics competes in the rare disease and oncology drug development market with Fulcrum Therapeutics (FSHD-focused, NASDAQ: FULC, losmapimod for FSHD), Arrowhead Pharmaceuticals (RNA interference for rare diseases), and transcription factor-focused startups for drug development funding and rare disease positioning. FSHD's unmet medical need (progressive muscle weakness, no approved treatment, large untreated patient population) creates orphan drug designation potential and expedited FDA review pathways. Y Combinator's W20 biotech backing connects Altay with the life sciences investor community for future Series A fundraising. The 2025 strategy focuses on completing lead optimization for the FSHD program, generating clinical candidate data package for IND application filing, and establishing partnerships with academic medical centers for natural history data access.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Altay Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Altay Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Altay Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Altay Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Altay Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →